Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).